Search clinical trials for: Neoadjuvant immunotherapy

Total 6980 results

Ottawa Hospital Research Institute
AstraZeneca; Hamilton Health Sciences Corporation; London Health Sciences Centre and other collaborators

Recruiting

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC (RADIANT)

Bladder Cancer

Canada
Tianjin Medical University Cancer Institute and...

Recruiting

Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer

Gastric Cancer

China
Guangdong Association of Clinical Trials

Recruiting

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Lung Cancer | Immunotherapy

China
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Peking University First Hospital; China-Japan Friendship Hospital

Recruiting

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Muscle-invasive Bladder Cancer | Upper Tract Urinary Carcinoma

China
Tongji Hospital

Not yet recruiting

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Multiple Pulmonary Nodules

China
The Netherlands Cancer Institute
Hoffmann-La Roche

Recruiting

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) (TARZAN)

Rectal Cancer

Netherlands
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
University of Louisville

Recruiting

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Cutaneous Melanoma

United States
Lawrence Fong
Genentech, Inc.

Recruiting

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Prostate Cancer | Prostate Adenocarcinoma | Localized Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Institute of Cancer Research, United Kingdom
AstraZeneca

Recruiting

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer (PHOENIX)

Breast Neoplasm

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC; Verastem, Inc.

Recruiting

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

United States
Institut Paoli-Calmettes
MSD France; Oncodistinct

Recruiting

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN)

Inflammatory Breast Cancer

France, Belgium
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Taiwan
The Netherlands Cancer Institute
Hoffmann-La Roche

Recruiting

Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA) (PANDA)

Stomach Cancer | Gastro Esophageal Junction Cancer

Netherlands
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)

Head and Neck Mucosal Melanomas

France
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (NICHE)

Colon Carcinoma

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
Craig L Slingluff, Jr

Recruiting

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

Pancreatic Cancer

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy (Neoadjuvant)

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
OncoSec Medical Incorporated

Active, not recruiting

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

Melanoma

United States
National Cancer Institute (NCI)

Completed

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Prostate Cancer

United States
UNICANCER

Active, not recruiting

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer (IMMUNEBOOST)

Oropharynx Cancer

France
Shanghai Zhongshan Hospital

Completed

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Esophagus Cancer

China
Sun Yat-sen University
Henan Cancer Hospital; Jiangmen Central Hospital

Completed

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Lung Cancer

China
Washington University School of Medicine
Merck Sharp & Dohme LLC

Active, not recruiting

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and Neck

United States
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC; Breast Cancer Research Foundation

Active, not recruiting

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

Breast Cancer | HER2-positive Breast Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma

Gastric Cancer

China
Wuhan Union Hospital, China
BeiGene

Active, not recruiting

Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer (CRISEC)

Neoadjuvant Therapy | Esophagus Cancer

China
AstraZeneca

Active, not recruiting

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC (NIAGARA)

Muscle Invasive Bladder Cancer

United States, Belgium, France, Germany, Italy, Spain, United Kingdom, Canada, Poland, Taiwan, Vietnam, Turkey, Korea, Republic of, Brazil, Czechia, Japan, Philippines, Israel, Chile, Australia, Netherlands, Russian Federation
Qiu Guoqin

Enrolling by invitation

Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma (CRIS)

Esophageal Squamous Cell Carcinoma

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)

Malignant Melanoma Stage III

United States, Netherlands, Australia
Shanghai Minimally Invasive Surgery Center

Suspended

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Gastric Cancer

China
M.D. Anderson Cancer Center

Completed

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE)

Breast Cancer | Triple Negative Breast Cancer | Luminal B

Belgium
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Active, not recruiting

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
The First Hospital of Jilin University

Active, not recruiting

Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer (Neo-Pre-IC)

IIIA Stage Non-small Cell Lung Cancer

China
Centre Leon Berard

Active, not recruiting

Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP)

Localized Resectable Tumor | MSI/dMMR or EBV-positive Gastric Cancers

France
Providence Health & Services
Eli Lilly and Company

Active, not recruiting

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Rectal Adenocarcinoma

United States
Asan Medical Center
Samsung Medical Center

Active, not recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer (DEBATE)

Cholangiocarcinoma | Biliary Tract Neoplasms | Gallbladder Cancer

Korea, Republic of
Sun Yat-sen University

Active, not recruiting

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer (SACTION01)

Carcinoma, Non-Small-Cell Lung

China
Daping Hospital and the Research Institute of Surgery...

Enrolling by invitation

PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer (PPIO-004-EC001)

Esophageal Squamous Cell Carcinoma

China
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Candel Therapeutics, Inc.
Mayo Clinic

Active, not recruiting

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma (PaTK02)

Borderline Resectable Pancreatic Adenocarcinoma

United States, Mexico
Tianjin Medical University Cancer Institute and...
Tianjin Medical University General Hospital; Tianjin Chest Hospital

Completed

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Delirium | Analgesia | NSCLC | Immunotherapy

China
Wuhan Union Hospital, China

Suspended

Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer

Rectal Cancer | Radiotherapy | Immunotherapy | Organ Preservation

China
University of Texas Southwestern Medical Center
Apexigen America, Inc.

Active, not recruiting

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

Locally Advanced Rectal Adenocarcinoma

United States

Search clinical trials for: Neoadjuvant immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations